Core Scientific Emerges from Bankruptcy, Issues New Common Stock
Ticker: CORZR · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1839341
| Field | Detail |
|---|---|
| Company | Core Scientific, Inc./Tx (CORZR) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $6.81, $0.01 |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: bankruptcy-exit, restructuring, common-stock, corporate-action
TL;DR
**Core Scientific is officially out of bankruptcy and has issued new stock, a huge positive for the company's future.**
AI Summary
Core Scientific, Inc. filed an 8-K on February 5, 2024, to disclose the effectiveness of its Plan of Reorganization and the issuance of new common stock. This means the company has officially emerged from bankruptcy, converting certain warrants into common stock at exercise prices of $6.81 and $0.01 per share. For investors, this is a significant positive step, as it signals the company has restructured its debt and can now focus on its core business, potentially leading to increased stability and growth for shareholders.
Why It Matters
This filing signals Core Scientific's successful emergence from bankruptcy, which is a critical step towards financial stability and future growth for the company and its investors. It resolves past financial distress and allows the company to operate with a cleaner balance sheet.
Risk Assessment
Risk Level: low — The filing indicates the successful completion of a major restructuring, significantly reducing financial uncertainty and risk for the company.
Analyst Insight
A smart investor would view this as a positive development, indicating the company has cleared a major hurdle. It might be a good time to re-evaluate Core Scientific's fundamentals and future prospects, considering the reduced financial risk.
Key Numbers
- $6.81 — Warrant Exercise Price (One of the exercise prices for warrants converted into common stock.)
- $0.01 — Warrant Exercise Price (Another exercise price for warrants converted into common stock.)
Key Players & Entities
- Core Scientific, Inc. (company) — the registrant filing the 8-K
- $6.81 (dollar_amount) — exercise price per share for certain warrants
- $0.01 (dollar_amount) — exercise price per share for certain warrants
- February 5, 2024 (date) — date of earliest event reported and filing date
- Nasdaq Global Select Market (exchange) — where Core Scientific's common stock is registered
Forward-Looking Statements
- Core Scientific will experience increased investor confidence and potentially a more stable stock price following its emergence from bankruptcy. (Core Scientific, Inc.) — medium confidence, target: Q2 2024
- The company will focus on operational growth and profitability now that its financial restructuring is complete. (Core Scientific, Inc.) — high confidence, target: Q4 2024
FAQ
What was the primary event reported by Core Scientific, Inc. in this 8-K filing?
The primary event reported was the effectiveness of Core Scientific, Inc.'s Plan of Reorganization, leading to its emergence from bankruptcy on February 5, 2024.
What is the significance of the 'Regulation FD Disclosure' item in this filing?
The 'Regulation FD Disclosure' item indicates that Core Scientific, Inc. is making public material non-public information to ensure fair disclosure to all investors, specifically regarding its emergence from bankruptcy and related stock issuance.
What were the exercise prices for the warrants mentioned in the filing that were converted into common stock?
The filing mentions two warrant exercise prices: $6.81 per share and $0.01 per share, both converted into common stock as of February 5, 2024.
Where is Core Scientific, Inc.'s common stock registered for trading?
Core Scientific, Inc.'s common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Global Select Market.
What was the former name of Core Scientific, Inc. before its name change?
The former name of Core Scientific, Inc. was Power & Digital Infrastructure Acquisition Corp., with the name change occurring on 20210106 (January 6, 2021).
Filing Stats: 584 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-02-05 09:27:10
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share CORZ The Nasdaq Global Sele
- $6.81 — of common stock at an exercise price of $6.81 per share CORZW The Nasdaq Global Sel
- $0.01 — of common stock at an exercise price of $0.01 per share CORZZ The Nasdaq Global Sel
Filing Documents
- core-20240205.htm (8-K) — 35KB
- januarypressrelease.htm (EX-99.1) — 42KB
- 0001628280-24-003172.txt ( ) — 265KB
- core-20240205.xsd (EX-101.SCH) — 3KB
- core-20240205_def.xml (EX-101.DEF) — 17KB
- core-20240205_lab.xml (EX-101.LAB) — 33KB
- core-20240205_pre.xml (EX-101.PRE) — 17KB
- core-20240205_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On February 5, 2024, the Company issued a press release announcing certain production and operations updates for the month of January 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language except as expressly set forth by specific reference in such filing.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release dated February 5 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Core Scientific, Inc. Dated: February 5, 2024 By: /s/ Todd M. DuChene Name: Todd M. DuChene Title: Chief Legal Officer and Chief Administrative Officer